-       Report 
- October 2025
-  187 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
          -       Report 
- September 2025
-  250 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- February 2025
-  200 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- September 2025
-  250 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- October 2025
-  50 Pages 
- Global 
   From       €2370EUR$2,650USD£2,085GBP 
              Bazedoxifene is a selective estrogen receptor modulator (SERM) used to treat endocrine and metabolic disorders. It is used to treat postmenopausal osteoporosis, as well as to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk for breast cancer. Bazedoxifene works by blocking the effects of estrogen in certain parts of the body, while also acting like estrogen in other parts of the body. This helps to reduce the risk of bone loss and breast    cancer.
Bazedoxifene is available in both oral and injectable forms. It is typically taken once daily, with or without food. Common side effects include hot flashes, nausea, and headache. Bazedoxifene should not be used by pregnant or breastfeeding women, or those with a history of stroke or blood clots.
The bazedoxifene market is a growing segment of the endocrine and metabolic disorders drugs market. It is used to treat a variety of conditions, including postmenopausal osteoporosis and breast cancer. As the population ages, the demand for bazedoxifene is expected to increase.
Some companies in the bazedoxifene market include Pfizer, Merck, and Eli Lilly. Show Less   Read more